Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. reported that director Ann Custin received an award of 2,354 common share stock units as equity compensation. The award was granted at no cash cost and increases her direct holdings to 24,086 common shares. The units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she continues as a service provider through that date.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received an award of 2,354 common share units at no cost under the company’s 2018 Equity Incentive Plan. The units vest in full on the earlier of May 22, 2027 or the day before the next annual meeting, if he continues as a service provider.
Following this grant, he holds 1,079,669 common shares directly and 19,090 common shares indirectly through his spouse.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Leslie Gillin received an award of 2,354 common share stock units as compensation. The award was granted at no cash cost to her and is tied to continued board service. These units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she remains a service provider through that date. Following this grant, she holds 18,398 common shares directly.
ESTABLISHMENT LABS HOLDINGS INC. saw affiliated investment funds managed by JW Asset Management report open-market sales of its Common Shares. On May 20, 2026, a total of 3,580 shares were sold at $70.56 per share, and on May 21, 2026, 16,999 shares were sold at $71.40 per share. Footnotes state these transactions reflect 15,350 shares sold by JW Partners, LP and 5,229 shares sold by JW Opportunities Fund, LLC. After these trades, the reporting group collectively reports holding 2,981,115 Common Shares indirectly. The Advisor, the General Partner and Jason G. Wild each disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. held its Annual Meeting of Shareholders on May 22, 2026. Shareholders elected six directors to serve until the 2027 annual meeting, including Filippo “Peter” Caldini, who received 20,009,113 votes for and 21,173 against, and Edward Schutter, who received 20,001,165 votes for and 29,105 against.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers with 19,999,556 votes for and 30,543 against, with 3,063,262 broker non-votes. In addition, they ratified the appointment of CBIZ, CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,686,230 votes for and 405,748 against.
Establishment Labs Holdings Inc. ownership table shows 1,578,119 common shares beneficially owned, representing 5.38% of the class as reported. The filing lists voting and dispositive powers across affiliated filers led by Brown Advisory Inc., with details of sole and shared voting/dispositive counts.
The schedule states the shares are held by investment companies and managed accounts of Brown Advisory subsidiaries and that Brown Advisory Inc. filed on behalf of those subsidiaries pursuant to the cited parent/subsidiary classification.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales of common shares executed on May 6, 2026 through entity Sariel Group Ltd, which holds the shares. The filing shows a total of 105,000 shares sold in two tranches under a pre-established Rule 10b5-1 trading plan, concluding that plan after all its shares were sold. Following these transactions, he continues to hold 45,193 common shares directly and 927,504 common shares indirectly through Sariel Group Ltd.
Establishment Labs Holdings Inc. reported first-quarter 2026 results showing strong growth but continued losses. Revenue rose to $59.9 million, up from $41.4 million a year earlier, driven by broader sales of Motiva Implants, including the United States.
Gross profit increased to $42.3 million, while the operating loss narrowed to $6.5 million and net loss improved to $13.4 million, or $0.45 per share. Cash and cash equivalents were $68.1 million, with net cash used in operating activities reduced to $4.3 million from $20.7 million. The balance sheet shows total assets of $351.0 million and shareholders’ equity of $14.8 million, alongside $246.4 million of Oaktree term debt and related obligations.
ESTABLISHMENT LABS HOLDINGS INC. had 60,000 Common Shares sold in an open-market transaction on May 6, 2026, by investment entities associated with JW Asset Management. The sale occurred at an average price of $75.625 per share and was executed indirectly through JW Partners, LP and JW Opportunities Fund, LLC.
After this sale, the reporting group collectively held 3,001,694 Common Shares indirectly. JW Asset Management, LLC, JW GP, LLC and Jason G. Wild each disclaim beneficial ownership of these securities except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. reported strong first-quarter 2026 results with revenue of $59.9 million, up 44.7% from the same period in 2025, driven by Motiva sales and minimally invasive products. Gross margin improved to 70.7%, and the company delivered its third consecutive quarter of positive adjusted EBITDA.
Net loss narrowed to $13.4 million from $20.7 million a year earlier, while cash used in the quarter fell to $7.5 million and cash on hand was $68.1 million as of March 31, 2026. Management raised full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million and now expects the minimally invasive business to exceed $35 million, with positive adjusted EBITDA every quarter and free cash flow positivity in the second half of 2026.